01
Attrition is the base rate
Most candidates entering clinical development never reach approval. Historical attrition means a phase 2 success should adjust your expectations modestly, not decisively.
Pipeline tracking is therefore most useful as a map of where scientific attention and capital are concentrated — not as a forecast of what will be available.
Fig. 02 / Molecular pathway02
What we track
This section monitors publicly disclosed peptide programmes by mechanism, indication, and stage, with links to registry entries and published reports where available.
- Incretin and nutrient-sensing mechanisms (metabolic).
- Peptide-drug and peptide-radionuclide conjugates (oncology).
- Long-acting formulations and oral peptide delivery platforms.
- Peptide antibiotics and antimicrobial peptides.
Editorial disclaimer
This site is educational and does not provide medical advice, dosing protocols, or treatment recommendations. Regulatory status and evidence strength differ sharply between compounds. A “research use only” label does not indicate that a product is appropriate for human use. Decisions about medicines belong with a qualified clinician.